BAY 94-9027 provides effective long-term prophylaxis in pediatric patients: Interim results of the PROTECT VIII Kids extension study

被引：0
|
作者：
Kenet, Gili [1 ]
Biss, Tina [2 ]
Steele, MacGregor [3 ]
Linardi, Camila [4 ]
Tseneklidou-Stoeter, Despina [5 ]
Saxena, Kapil [4 ]
机构：
[1] Chaim Sheba Med Ctr, Israel Natl Hemophilia Ctr, Tel Hashomer, Israel
[2] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
[3] Univ Calgary, Alberta Childrens Hosp, Cumming Sch Med, Calgary, AB, Canada
[4] Bayer, Whippany, NJ USA
[5] Bayer, Berlin, Germany
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
M-FPMED02-
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [31] Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study
    Santagostino, Elena
    Kerlin, Bryce A.
    Negrier, Claude
    Tian, Liu
    Ducore, Jonathan M.
    [J]. BLOOD, 2018, 132
  • [32] HIGH ESTIMATED SUCCESS RATE FOR EVERY-5-DAY PROPHYLAXIS WITH BAY 94-9027: DATA FROM PROTECT VIII
    Mancuso, Maria
    Rangarajan, Savita
    Liu, Tian
    Lalezari, Shadan
    Ducore, Jonathan
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66
  • [33] High estimated success rate for every-5-day prophylaxis with BAY 94-9027 based on data from the protect VIII study
    Mancuso, M. Elisa
    Rangarajan, S.
    Liu, T.
    Lalezari, S.
    Ducore, J.
    [J]. HAEMOPHILIA, 2019, 25 : 129 - 129
  • [34] CONSISTENT CONTROL OF BLEEDS AMONG PATIENTS WITH HAEMOPHILIA A AGED >40 YEARS TREATED WITH PROPHYLACTIC BAY 94-9027 IN THE PROTECT VIII STUDY AND ITS EXTENSION
    Ducore, J.
    Holme, P. A.
    Lalezari, S.
    Mancuso, M. -E.
    Enriquez, M. Maas
    Bayh, I.
    Reding, M.
    [J]. HAEMOPHILIA, 2020, 26 : 101 - 102
  • [35] Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data
    Miesbach, Wolfgang A.
    Di Minno, Giovanni
    Santagostino, Elena
    Klamroth
    Bayh, Inga
    Soto, Amaryllis
    Hermans, Cedric
    [J]. BLOOD, 2019, 134
  • [36] BAY 94-9027 is efficacious in maintaining hemostasis during major surgery in adults and adolescents with severe hemophilia A: protect VIII results
    Santagostino, E.
    Lalezari, S.
    Ducore, J.
    Michaels, L. A.
    Saxena, K.
    Linardi, C.
    [J]. HAEMOPHILIA, 2018, 24 : 69 - 69
  • [37] Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial
    Santagostino, Elena
    Lalezari, Shadan
    Reding, Mark T.
    Ducore, Jonathan
    Ng, Heng Joo
    Poulsen, Lone H.
    Michaels, Lisa A.
    Linardi, Camila C. G.
    [J]. THROMBOSIS RESEARCH, 2019, 183 : 13 - 19
  • [38] Bleeding outcomes during the last 90 days of treatment with BAY 94-9027: Results from a post-hoc analysis of the PROTECT VIII study
    Liu, T.
    Reding, M.
    Chalasani, P.
    Ahuja, S.
    Eyster, E.
    [J]. HAEMOPHILIA, 2019, 25 : 42 - 42
  • [39] Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study
    Church, N.
    Leong, L.
    Katterle, Y.
    Ulbrich, H. -F.
    Noerenberg, I.
    Kitchen, S.
    Michaels, L. A.
    [J]. HAEMOPHILIA, 2018, 24 (05) : 823 - 832
  • [40] Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study
    Ducore, Jonathan M.
    Lalezari, Shadan
    Santagostino, Elena
    Ahuja, Sanjay P.
    Enriquez, Monika Maas
    Tueckmantel, Claudia
    Reding, Mark
    [J]. BLOOD, 2019, 134
12345